05.10.2021

Crafting a Cure for Diabetic Neuropathic Pain, Molecule by Molecule (Published by NIH)

A team of scientists at Knopp Biosciences LLC is innovating treatments to manage neuropathic pain by aiming at its source — hyperactive nerve cells.

Read the entire article from the NIH here!

FacebookTwitterLinkedIn

Keep reading

05.17.21

Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Discover this News

05.13.21

Knopp Biosciences to Present Details of Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Discover this News

01.14.21

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Discover this News

11.11.20

Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers

Discover this News

10.08.20

Knopp Biosciences NIH-funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News